The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

The symptoms of MSA are wide-ranging and include muscle control problems, similar to those of Parkinson's disease. Many different functions of the body can be affected, and symptoms including ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

A new study published in JAMA Network Open found a connection between dementia risk and seven heart-healthy habits. Habits ...

As Australian shares brace for a potential downturn, with the ASX 200 futures indicating a significant drop, investors are keenly observing market movements and their implications. In such volatile ...

If you want to read more about the recent tariffs imposed by the US you can look at the 10 Most Undervalued High Quality ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the advancement of the Phase 1/Phase 2 LION-CS101 clinical trial of ...